CSPC Innovation Pharmaceutical optimizes idle funds with cash management

CSPC Innovation Pharmaceutical Co., Ltd. announced progress in its cash management activities utilizing idle raised funds. Following shareholder approval on April 15, 2024, the company and its subsidiaries are authorized to manage up to RMB 800 million of idle raised funds and up to RMB 800 million of self-owned funds in secure, liquid, principal-protected products. This authorization is valid for 12 months and allows for revolving operations.

As of the announcement date, the company has a total of RMB 40,500,000 in idle raised funds currently under cash management that have not yet matured. Recently, one product, a structured deposit from China Everbright Bank with a principal of RMB 5,000,000, matured on November 14, 2025, yielding RMB 21.88. Concurrently, the company deployed RMB 2,500,000 into another structured deposit product with China Everbright Bank, commencing on November 14, 2025, and maturing on February 14, 2026, with an expected annualized yield of 1%/1.6%/1.7%.

The company emphasizes that these cash management activities, involving principal-protected products, do not impact the construction of its fundraising projects or its normal operations. This approach aims to improve capital utilization efficiency and increase investment returns, aligning with the interests of its shareholders and overall development strategy.